Trial Profile
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Seribantumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 11 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Dec 2014 Results published in a Merrimack Pharmaceuticals media release.
- 11 Dec 2014 Results presented at the 37th Annual San Antonio Breast Cancer Symposium.